Micellar High Performance Liquid Chromatographic Method for Simultaneous Determination of Clonazepam and Paroxetine HCl in Pharmaceutical Preparations Using Monolithic Column

Fawzia Ibrahim, Nahed El-Enany, Shereen Shalan and Rasha Elsharawy*
Department of Analytical Chemistry, Faculty of Pharmacy, University of Mansoura, Mansoura, Egypt

Abstract
A new and accurate micellar high performance liquid chromatographic method coupled with ultraviolet detection was developed for simultaneous determination of Clonazepam (CLZ) and Paroxetine (PRX) using a monolithic C-18 column, and mobile phase consisting of 0.175M Sodium dodecyl sulphate, 12% n-propanol prepared in 0.02M phosphoric acid at pH 6.0. The analysis was performed at a flow rate of 1 mL/min with ultraviolet-detection at 300 nm. The method was linear over the concentration range (1.0-20 µg) and (4.0-250 µg) with limits of detection of 0.277, 2.675 µg/mL and limits of quantification of 0.838, 8.106 µg/mL for CLZ and PRX respectively. The average % recovery was found to be 100.08 ± 1.31 and 100.22 ± 1.15 for CLZ and PRX respectively. Method validation according to ICH Guidelines recommendation was evaluated. Statistical analysis of the results obtained by the proposed method was compared successfully with those obtained using the reference one. There was no significance difference between the two methods regarding accuracy and precision respectively.

Keywords: Micellar liquid chromatography; Ultraviolet detection; Clonazepam; Paroxetine; Co-formulated tablets; Method validation

Introduction
Clonazepam (5-(2-Chlorophenyl)-7-nitro-2,3-dihydro-1,4-benzodiazepin-2-one) (Figure 1) is a benzodiazepine drug having anxiolytic, anticonvulsant, muscle relaxant, sedative, and hypnotic properties [1]. Clonazepam is used to eliminate seizure activity, anxiety, mania, panic disorders and schizophrenia as it calms brain and nerves [2]. For these reasons, Clonazepam has been identified as a promising drug. Some of the commonly side effects are restless, changing mood, hyperactive and aggressive [3]. The British Pharmacopoeia [4] recommends non-aqueous titration with perchloric acid for the determination of clonazepam. For dosage forms, high-pressure liquid chromatography (HPLC) is recommended by US Pharmacopoeia [5]. Several methods have been reported for determination of this compound including spectrophotometric methods [6-8], potentiometric methods [9,10], voltammetry [11], palarography [12], HPLC [12-14] and gas chromatography coupled with mass spectrometry (GC-MS) [13,15].

Paroxetine ((3S,4R)-3-[(2H-1,3-benzodioxol-5-yl)oxy]methyl)-4-(4-fluorophenyl)piperidine) (Figure 1) is an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) type. Paroxetine is used to treat major depression, obsessive-compulsive disorder, panic disorder, anxiety, posttraumatic, generalized anxiety disorder and vasomotor symptoms (e.g., hot flashes and night sweats) associated with menopause [16,17] in adult outpatients. Paroxetine is primarily used to treat major depression, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), panic disorder, generalized anxiety disorder (GAD) [18] social phobia/social anxiety disorder [19] premenstrual dysphoric disorder (PMDD) [20] and menopausal hot flashes.

Paroxetine was the first antidepressant formally approved in the United States for the treatment of panic attacks [21].

The previously published methods that concerned with quantitative determination of PRX in tablets include voltammetry [22,23], densitometry [24,25], high-performance liquid chromatography [26-31], gas chromatography [32-34], capillary electrophoresis [35] and spectrofluorimetry [36].

Paroxetine co administered with clonazepam demonstrated significant improvement by endpoint. Combined treatment with paroxetine and clonazepam resulted in more rapid response than with the SSRI alone [37].

Up till now there was not any micellar HPLC method for simultaneous determination of Paroxetine and Clonazepam in the tablet dosage forms. There is one method for the simultaneous determination of clonazepam and paroxetine by RP-HPLC [38]. Our method is more sensitive and we use a smaller amount of organic solvent comparing to the other method (using 60% acetonitrile). For these reasons we are encouraged to perform the present work which determines CLZ and PAX simultaneously using monolithic column.

Experimental

Apparatus
HPLC using a Chromatograph separation was carried out using a (Merck Hitachi model L-7100) equipped with a Rhodyne injector valve with a 20 µl loop, and an ultraviolet detector (Merck Hitachi L-7400), operated at 300 nm. The chromatograms were recorded on a Shimadzu C-R6A integrator. Mobile phase was filtered using membrane filters (Millipore, Ireland) and degassed using Merck solvent L-7126 degasser. pH-meter used is Consort P-901. Ultrasonic bath, model SS 101 H 230, USA.

*Corresponding author: Rasha Elsharawy, Department of Analytical Chemistry, Faculty of Pharmacy, University of Mansoura, 35516, Mansoura, Egypt, Tel: +201093335779; E-mail: rasha.elsharawy@yahoo.com

Received July 11, 2016; Accepted July 28, 2016; Published August 03, 2016

Citation: Ibrahim F, El-Enany N, Shalan S, Elsharawy R (2016) Micellar High Performance Liquid Chromatographic Method for Simultaneous Determination of Clonazepam and Paroxetine HCl in Pharmaceutical Preparations Using Monolithic Column. J Chromatogr Sep Tech 7: 331. doi: 10.4172/2157-7064.1000331

Copyright: © 2016 Ibrahim F. et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Materials and reagents

- Clonazepam CLZ: was kindly provided from Egyptian International Pharmaceutical Industry Company (EIPICO), with a purity of 99.3% as determined by the comparison method.
- Paroxetine HCl: was kindly provided by Pharaon pharmaceuticals company (Alexandria, Egypt), with a purity of 99.8% as determined by the comparison method.
- Sodium dodecyl sulphate (SDS) 90% and orthophosphoric acid 85% were obtained from Riedel-deHäen (Germany).
- Methanol and n-propanol (HPLC grade) were obtained from Sigma-Aldrich (Germany).
- Amotril® tablets product of (Amoun Pharmaceutical Co. El Obour city, Cairo, Egypt), labeled to contain 0.5 mg clonazepam. (Batch no. ≠131777).
- Seroxat® CR tablets product of (GlaxoSmithKline Inc, 7333 Mississauga Road North, Canada) labeled to contain 12.5 mg Paroxetine HCL. (batch no. ≠A103035).
- Laboratory prepared co-formulated tablets (0.25 mg clonazepam, 12.5 mg Paroxetine HCl, 20 mg talc powder, 15 mg starch, 15 mg lactose and 10 mg magnesium stearate per tablet).
- All the pharmaceuticals used were obtained from Egyptian market.

Chromatographic conditions: Chromolith® speed ROD C-18 (50 mm × 4.6 mm i.d., 2 µm particle sizes), Merck, Germany. Mobile phase: a solution consists of a mixture of 12% n-propanol and 0.175 SDS and the pH was adjusted to 6.0 using orthophosphoric acid. The mobile phase was filtered through Millipore membrane filter. Flow rate: 1 mL/min. Ultraviolet detection: 300 nm.

Standard solutions: Stock solutions were prepared by dissolving either 10.0 mg of CLZ or 10.0 mg PRX in 100.0 mL of methanol to give solution containing 100 µg/mL using ultrasonic bath for good solubility. Working standard solutions were prepared by appropriate dilution of the stock solutions with methanol. All solutions were stored in the refrigerator at 2°C and found to be stable for at least 7 days.

Procedures

Different volumes of the drug working standard solutions were accurately conveyed into a series of 10.0 mL volumetric flasks to obtain the final concentrations in the range of 1.0-20 µg/mL for CLZ and 4.0-250 µg/mL for PRX. Then the volumes of solutions were completed to the mark with the mobile phase and pH was adjusted at 6.0 and mixed well.

Volumes of 20.0 µL were injected (triplicate) and eluted with the mobile phase under the optimum chromatographic conditions. The peak areas against the final concentration of the drugs in µg/mL were drawn. And the corresponding regression equations were obtained.

Analysis of CLZ/PRX laboratory prepared mixtures by the proposed method: Aliquots of CLZ and PRX standard solutions at a pharmaceutical ratio of 1:50 [39]. Were transferred into a series of 10.0 mL volumetric flasks. The solutions were diluted to the volume with the mobile phase and mixed well. Procedure described under “Construction of the Calibration Graphs” was then applied. The mean percentage recoveries were calculated by referring to the calibration graphs, or using the corresponding regression equations.

Analysis of the two drugs in their single tablets by the proposed method: The content of ten tablets (Amotril®, Seroxat® CR) were accurately weighed, finely powdered, and thoroughly mixed. Accurately weighed amounts of the powdered tablets equivalent to 0.5 mg of CLZ or 12.5 mg of PRX were transferred into a 100 mL volumetric flask and extracted with 80 mL of methanol. The contents of the flask were sonicated for 30 min, completed to the volume with the same solvent and filtered. Filtration utilizing syringe filter was performed to get clear solutions. Aliquots containing suitable concentrations of the studied drugs were analyzed as described under “construction of the calibration graphs”. The nominal content of each drug was calculated either from a previously plotted calibration graph or by using the corresponding regression equation.

Analysis of the two drugs in their laboratory prepared co-formulated tablets by the proposed method: Co-formulated tablets were prepared, according to their pharmaceutical ratio (1:50). Weighed quantity of mixed laboratory prepared tablets equivalent to 0.25 mg CLZ and 12.5 mg PRX were transferred into 100 mL volumetric flasks and about 80 mL of methanol were added. The contents of the flask were sonicated for 30 min, completed to the volume with the same solvent and filtered twice using syringe filters to get highly clear filtrate. Volumes containing different concentrations of CLZ and PRX were taken and analyzed as described under construction of the calibration graphs. The content of each drug was calculated either from the already plotted calibration graphs or by using the corresponding regression equations.

Results and Discussion

A micellar HPLC method coupled with ultraviolet detection was developed and fully validated for the simultaneous determination of CLZ and PRX.

The proposed method can separate CLZ and PRX with good resolution, as the retention time between CLZ and PRX less than 5 min. The experimental parameters influencing the chromatograms of the studied drugs were accurately considered and optimized. The optimal parameter gives the highest number of theoretical plates and the best resolution within a reasonable time. Figure 2 shows a typical chromatogram for laboratory prepared mixture of CLZ and PRX under the described chromatographic conditions and the detection was performed at 300 nm. The separation was achieved within short retention time (tR=1.36 and 4.9 min) for CLZ and PRX, respectively.

Optimization of the chromatographic performance and system suitability

- Study of experimental parameters: Different experimental conditions affecting chromatographic behavior and determination of
the studied drugs including; type of column, concentration of SDS, pH of the mobile phase, concentration of the organic modifier and detection wavelength were carefully studied and optimized.

Choice of column: Two different columns were tried for performance investigations, including; Promosil ODS C18 column (250 × 4.6 mm i.d., 5 µm particle size), Agela Technologies, USA and Chromolith® speed ROD C-18 (50 mm × 4.6 mm i.d., 2 µm particle sizes), Merck, Germany. Experimental studies revealed that, the second column was the appropriate one, giving symmetrical, well defined peaks with good resolution within reasonable time. The first column was not suitable as it showed disturbed overlapped peaks.

Concentration of SDS: The effect of the concentration of SDS on the selectivity and retention time of the drugs was studied using mobile phase containing concentration of 0.1 to 0.2M SDS. It was found that 0.175M of SDS was the optimum conc.

pH of the mobile phase: The influence of pH changing on the retention time of CLZ and PRX was studied over the range of (4.0-6.5). pH 6.0 was the most appropriate pH as it gives symmetrical peaks within reasonable time and high number of theoretical plates as shown in Table 1.

Type of organic modifier: Different organic modifiers were tried including methanol, n-propanol and n-butanol. It was found that n-propanol was the organic modifier of choice as it gives the most symmetrical separated peaks. Methanol was found to give a precipitate in the mobile phase and n-butanol gives non symmetrical peaks.

Concentration of organic modifier: The effect of increasing the % concentration of n-propanol on the chromatographic behavior was studied over the range of (8% -14%). It was found that 12% (v/v) was the most appropriate concentration as it gives the highest number of theoretical plates and good resolution.

Choice of detection wavelengths: The effect of changing wavelength on the chromatographic behavior of both drugs was investigated over the range (290-320 nm). We use the wavelength that gives the maximum peak for paroxetine to enable us to determine both drugs simultaneously. It was found that 300 nm was the most suitable wavelength found for the determination and separation since it gives the symmetrical peaks for both drugs with high number of theoretical plates and good resolution.

Development and validation of the analytical method

The validity of the proposed method was tested regarding linearity, specificity, accuracy, repeatability and precision according to ICH Q2R1 recommendations [40].

Linearity and range: Using the proposed procedure, a linear regression equation was obtained. The regression plot showed that there was a linear relationship established by plotting the peak area against the drug concentration µg/mL. Linear regression analysis of the data gave the following equation:

\[ P = -20657.1 + 53108C \]  \( (r=0.9998) \) for CLZ

\[ P = -19856.2 + 12613.3C \]  \( (r=0.9999) \) for PRX

Where the P is the peak area, C is the concentration of the drug in µg/mL and r is the correlation coefficient.

Statistical analysis [41] of the data gave a reasonable value of the correlation coefficient (r) of the regression equation, accepted value of the standard deviation of residuals (Sy/x), standard deviation of intercept (Sb), and standard deviation of slope (Sa), and accepted value of the percentage relative standard deviation and the percentage relative error (Table 2). These data proved the linearity of the calibration curve and low scattering of the points around the calibration curve.

Limit of Quantitation (LOQ) and limit of detection (LOD): The limit of quantitation (LOQ) is the minimal concentration which can be determined based on ICH Q2R1 recommendations (40) under which the calibration plot is non linear.

The limit of detection (LOD) is the minimum analyte concentration which can be detected (41).

\[ \text{LOD} = 3.3 \frac{S_a}{b} \]

\[ \text{LOD} = 10 \frac{S_a}{b} \]

Where \( S_a \) = standard deviation of the intercept of the calibration curve and \( b = \) slope of the calibration curve.

LOQ and LOD values for CLZ and PRX by the suggested method were showed in Table 2. LOQ values are 0.838 and 8.106 µg/mL while LOD values are 0.277 and 2.675 µg/mL for CLZ and PRX, respectively.

Accuracy: The accuracy of the proposed method was proved by comparing the results of the proposed method with those obtained...
using the comparison chromatographic methods [42,43] for CLZ and PAX respectively. The comparison method for CLZ involved the use of methanol and ammonium phosphate (50:50 v/v) adjusted to pH 8.0 and detected ultravioletly at 254 nm, and for PAX involved the use of dipotassium hydrogen phosphate and Acetonitrile (90: 10 v/v), adjusted to pH 6.5 and detected spectrophotometrically at 295 nm. Statistical analysis of the results obtained by the proposed method and comparison methods using Student’s t-test and variance ratio F-test [41] revealed no significant difference between the performance of the two methods regarding the accuracy and precision, respectively (Table 3).

**Precision**

**I. Intra-day precision**: Intra-day precision was assessed through replicate analysis of three concentrations of the studied drugs on three successive times within the same day. The results are shown in Table 5.

**II. Inter-day precision**: Inter-day precision was assessed through replicate analysis of three concentrations of the studied drugs on three successive days. The results are summarized in Table 4.

**Robustness of the method**: The robustness of the method was assessed by evaluating the influence of small variation of experimental variables: concentrations of organic modifier (12% ± 1), pH (6.0 ± 0.1), and conc. of SDS (0.175M ± 0.01) on the analytical performance of the method. In these experiments, one experimental parameter was changed while the other parameters were kept unchanged, and the recovery percentage was calculated each time. The minor changes in these experiment parameters did not significantly affect the peak areas; recovery percentage in case of CLZ is 100.08 ± 1.31 and in case of PAX is 100.22 ± 1.15 respectively.

**Selectivity**: The proposed MLC method was considered selective by detecting any change resulted from common tablet additives such as lactose, starch, magnesium stearate, and talc. The high mean % recovery and high accuracy with low SD indicated that excipients did not affect the results of the proposed method.

**Applications**

Application of the proposed method to the analysis of CLZ/PRX laboratory prepared mixtures: CLZ and PAX can be determined in laboratory prepared mixtures simultaneously by the suggested method in ratios of 1:50 (Figure 3). Both drugs can be quantitated in laboratory prepared mixtures simultaneously by the suggested method.

**Pharmaceutical application**

Application of the proposed method to the analysis of laboratory prepared co-formulated tablets: The proposed method was successfully applied to the estimation of CLZ and PAX in their laboratory prepared co-formulated tablets. The results listed in Table 6 show a good agreement with those by the official method [42,43]. Student’s t-test and variance ratio F-test [41] analyzed the results obtained by the proposed method and showed no significant difference.
between it and the official method [42,43] concerning the accuracy and precision, respectively. Good recoveries, 100.02 ± 0.59 and 100.19 ± 1.33 were achieved for CLZ and PRX respectively, from their prepared tablets in 1:50 ratio, respectively. Figure 4 shows chromatograms indicating good resolved peaks of CLZ and PRX in their laboratory prepared co-formulated tablets.

**Analysis of CLZ and PRX tablets:** The proposed method was successfully applied to the assay of the studied drugs in single dosage forms. The results of the proposed method were favorably compared with those obtained using the comparison method [42,43]. Mean percent recoveries from Amotril® 0.5 mg CLZ tablets and Seroxat® CR 12.5 mg PRX tablets were 99.96 ± 0.59 and 99.99 ± 1.27, respectively.

The results shown in Table 7 are in good agreement with those obtained with the comparison method [42,43]. Statistical analysis of the results obtained using Student’s t-test and variance ratio F-test [41] revealed no significant difference between the performance of the two methods regarding the accuracy and precision, respectively. Figure 5 shows chromatograms indicating good resolved peaks of CLZ and PRX in their dosage forms.

**Conclusion**

A simple, accurate and validated chromatographic method with ultraviolet detection was proposed for the simultaneous determination...
Parameters | CLZ Conc. (µg/mL) | PRX Conc. (µg/mL) |
|---|---|---|
| 2 | 4 | 6 | 50 | 100 | 150 |

| Intraday | % Found | ( x ) | % RSD | ± S.D. |
|---|---|---|---|---|
| 99.44 | 100.74 | 99.59 | 101.91 | 98.80 | 98.69 |
| 99.17 | 100.03 | 100 | 100.62 | 98.81 | 98.41 |
| 100.04 | 98.97 | 100.76 | 99.92 | 100.36 | 99.79 |
| ( x ) | 99.54 | 99.91 | 100.12 | 100.82 | 99.66 | 98.66 |
| ± S.D. | ± 0.46 | ± 0.89 | ± 0.59 | ± 1.01 | ± 0.79 | ± 0.73 |
| %RSD | 0.46 | 0.89 | 0.59 | 1.00 | 0.79 | 0.74 |
| % Found | 99.74 | 99.32 | 100.29 | 101.33 | 99.39 | 98.13 |
| ( x ) | 99.95 | 00.15 | 100.37 | 101.41 | 99.80 | 98.59 |
| ± S.D. | ± 0.64 | ± 0.74 | ± 0.82 | ± 0.47 | ± 0.42 | ± 0.58 |
| %RSD | 0.64 | 0.74 | 0.82 | 0.46 | 0.42 | 0.59 |

Table 4: Precision data for the determination of CLZ and PRX in pure form by the proposed method.

| Conc. taken (µg/mL) | Conc. found (µg/mL) | % Found | % Found | % Found | % Found |
|---|---|---|---|---|---|
| CLZ | PRX | CLZ | PRX | CLZ | PRX | CLZ | PRX |
| 2 | 50 | 1.96 | 50.96 | 98.21 | 101.91 | 98.51 | 100.36 |
| 4 | 100 | 4.08 | 99.66 | 101.93 | 99.66 | 100.28 | 100.65 |
| 6 | 150 | 5.95 | 147.82 | 99.23 | 98.55 | 100.55 | 98.90 |
| 8 | 200 | 8.00 | 201.57 | 100.07 | 100.78 | 100.61 | 100.15 |
| X;¯ | 99.86 | 100.23 | 99.99 | 100.01 |
| ± SD | 1.58 | 1.45 | 1.00 | 0.77 |
| % RSD | 1.578 | 1.443 |
| % Error | 0.788 | 0.723 |
| T-test | 0.136 (2.4)* | 0.27 (2.4)* |
| F-test | 2.5 (9.27)* | 3.56 (9.27)* |

N.B. *The value between parenthesis are the tabulated t and F values at P = 0.05

Table 5: results for the analysis of CLZ and PRX in their laboratory prepared mixtures.

| Conc. taken (µg/mL) | Conc. found (µg/mL) | % Found | % Found | % Found | % Found |
|---|---|---|---|---|---|
| CLZ | PRX | CLZ | PRX | CLZ | PRX |
| 2 | 50 | 2.01 | 50.97 | 100.36 | 98.75 | 101.93 | 98.85 |
| 4 | 100 | 3.97 | 98.75 | 99.28 | 98.75 | 101.4 | 99.36 |
| 6 | 150 | 6.04 | 149.6 | 100.61 | 99.74 | 100.36 | 101.32 |
| 8 | 200 | 7.99 | 200.68 | 99.81 | 100.34 | 100.65 | 100.36 |
| X;¯ | 100.02 | 100.19 | 100.32 | 100.56 |
| ± SD | 0.59 | 1.33 | 1.07 | 0.91 |
| % RSD | 0.593 | 1.329 |
| % Error | 0.297 | 0.666 |
| T-test | 0.49 (2.44)* | 0.46 (2.44)* |
| F-test | 3.26 (9.27)* | 2.15 (9.27)* |

N.B. *The value between parenthesis are the tabulated t and F values at P=0.05

Table 6: Results for the analysis of CLZ and PRX in their prepared tablets by the proposed and comparison methods.
Table 7: Determination of CLZ and PRX in their single tablets by the proposed and comparison methods.

| Pharmaceutical preparation | Proposed method | Comparison method |
|----------------------------|-----------------|-------------------|
|                            | Conc. taken (µg/mL) | Conc. found (µg/mL) | % Found | % Found |
| Amotril® tablets (0.5 mg CLZ/tablet) | 2 | 1.99 | 99.44 | 100.4 |
|                            | 4 | 4.03 | 100.74 | 101.98 |
|                            | 6 | 5.98 | 99.59 | 99.65 |
|                            | 8 | 8.01 | 100.08 | 100.12 |
| AX;¯E | | | 99.96 | 100.54 |
| ± SD | | | 0.59 | 1.01 |
| % RSD | | | 0.586 | |
| % Error | | | 0.293 | |
| t-test | | | 0.98 | (2.44)* |
| F-test | | | 2.97 | (9.27)* |
| Seroxat® CR tablets (12.5 mg PRX/tablet) | 50 | 50.08 | 100.16 | 98.96 |
|                            | 80 | 79.01 | 98.77 | 94.43 |
|                            | 100 | 101.69 | 101.69 | 101.39 |
|                            | 120 | 119.21 | 99.34 | 99.98 |
| AX;¯E | | | 99.99 | |
| ± SD | | | 1.27 | |
| % RSD | | | 1.269 | |
| % Error | | | 0.635 | |
| t-test | | | 0.06 | (2.44) * |
| F-test | | | 1.45 | (9.27)* |

N.B.
*The value between parenthesis are the tabulated t and F values at P<0.05

of CLZ and PRX in binary mixtures. In addition, it could be applied to the analysis of both drugs in their single and laboratory prepared co-formulated dosage forms without any interference from the common excipients and the results show good agreement with those obtained by the comparison method.

References
1. Cowen PJ, Green AR, Nutt DJ (1981) Ethyl beta-carboline carboxylate lowers seizure threshold and antagonizes flurazepam-induced sedation in rats. Nature 290: 54-55.
2. Browne TR (1976) Clonazepam A review of a new anticonvulsant drug. Arch Neurol 33: 326-332.
3. Tomson T, Svanborg E, Wedlund JE (1986) Nonconvulsive status epilepticus: high incidence of complex partial status. Epilepsia 27: 276-285.
4. The British Pharmacopoeia 98/34/EEC (2005) London: The Stationery Office.
5. United States Pharmacopoeia (2004) USP-27/NF-22. Rockville: Authority of the United States Pharmacopoeia Convention.
6. El-Brashy A, Aly FA, Belal F (1993) Determination of 1,4-benzodiazepines in drug dosage forms by difference spectrophotometry. Microchim Acta 110: 55-60.
7. Salem AA, Barsoum BN, Izake EL (2002) Determination of bromazepam and clonazepam in pure and pharmaceutical dosage forms using chloranil as a charge transfer complexing agent. Anal Lett 35: 1631-1648.
8. Salem AA, Barsoum BN, Izake EL (2004) Spectrophotometric and fluorimetric determination of diazepam, bromazepam and clonazepam in pharmaceutical and urine samples. Spectrophotact Acta Part A 60: 771-780.
9. Nie L, Liu D, Yao SJ (1990) Potentiometric determination of diazepam with a diazepam ion-selective electrode. Pharm Biomed Anal 8: 379-383.
10. Salem AA, Barsoum BN, Izake EL (2003) Potentiometric determination of diazepam, bromazepam and clonazepam using solid contact ion-selective electrodes. Anal Chim Acta 498: 79-91.
11. Correia dos Santos MM, Fialia V, Goncalves ML (2002) Square-wave voltammetric techniques for determination of psychoactive 1,4-benzodiazepine drugs. Anal Bioanal Chem 374: 1074-1081.
12. Wilhelm M, Battista HJ, Obendorf D (2000) Development of Indirect Spectrophotometric Method for the Determination of Clonazepam in pharmaceutical preparation Using Resorcinol. J Chromatogr A 897: 215-225.
13. Cavedal LE, Mendes FD, Domingues CC, Patni AK, Monif T, et al. (2007) Clonazepam quantification in human plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry in a bioequivalence study. J Mass Spectrom 42: 81-88.
14. Gandhi SV, Dhavale ND, JadHAV VZ, Sabnis SS (2008) Spectrophotometric and Reversed-Phase High-Performance Liquid Chromatographic Methods for Simultaneous Determination of Escitalopram Oxalate and Clonazepam in Combined Tablet Dosage Form. JAOAC Int 91: 33-38.
15. Pujadas M, Pichini S, Civit E, Santamarina E, Perez K, et al. (2007) A simple and reliable procedure for the determination of psychoactive drugs in oral fluid by gas chromatography-mass spectrometry. J Pharm Biomed Anal 44: 594-601.
16. Katzman MA (2009) Current considerations in the treatment of generalized anxiety disorder. CNS Drugs 23: 103-120.
17. Food and Drug Administration (2013) FDA News release: FDA approves the first non-hormonal treatment for hot flashes associated with menopause.
18. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, et al. (2005) Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 19: 567-596.
19. Baldwin D, Bobes J, Stein DJ, Schwanitzcher I, Faure M (1999) Paroxetine in social phobia/social anxiety disorder. Randomised,double-blind, placebo-controlled study. Paroxetine Study Group. The British Journal of Psychiatry 175: 120-125.
20. Yonkers KA, Gullion C, Williams A, Novak K, Rush AJ (1996) Paroxetine as a treatment for premenstrual dyshoric disorder. Journal of Clinical Psychopharmacology 16: 3-8.

21. Turner FJ (2005) Social Work Diagnosis in Contemporary Practice. Oxford University Press, USA.

22. Nouis HPA, DelerueMatos C, Barros AA, Rodrigues JA (2006) Electroanalytical determination of paroxetine in pharmaceuticals. Journal of Pharmaceutical and Biomedical Analysis 42: 341-346.

23. Erik N, Biryol J (2003) Voltammetric and HPLC techniques for the determination of paroxetine hydrochloride. Pharmazie 58: 699-704.

24. Robert S, Genowefa M, Marcin K (2003) Determination of fluoxetine and paroxetine in pharmaceutical formulations by densitometric and videodensitometric TLC. Journal of Planar Chromatography-Modern TLC 1: 19-22.

25. Venkatachalam A, Chatterjee VS (2007) Stability indicating high performance thin layer chromatography determination of Paroxetine hydrochloride in bulk drug and pharmaceutical formulations. Analytica Chimica Acta 590: 312-317.

26. Zainaghi IA, Lanchote VL, Queiroz RHC (2003) Determination of paroxetine in geriatric depression by high performance liquid chromatography. Pharmacological Research 53: 217-221.

27. Zhu Z, Neirinck L (2002) High-performance liquid chromatography/mass spectrometry method for the determination of paroxetine in human plasma. Journal of Chromatography B 781: 295-300.

28. Massaroti P, Cassiano NM, Duarte LF (2005) Validation of a selective method for determination of Paroxetine in human plasma by LC MS/MS. Journal of Pharmacy and Pharmaceutical Sciences 8: 340-347.

29. Jhee OH, See HK, Lee MH (2007) Determination of paroxetine in plasma by liquid chromatography coupled to tandem mass spectrometry for pharmacokinetic and bioequivalence studies. Arzneimittel-Forschung 57: 455-461.

30. British Pharmacopoeia (2003) The Stationary Office, London, UK.

31. United States Pharmacopeial Convention (2008) The United States Pharmacopeia 31. The National Formulary 26, United States Pharmacopeia, Rockville, MD, USA.

32. Eap CB, Bouchoux G, Arney M, Cochard N, Savary L, et al. (1998) Simultaneous determination of human plasma levels of citalopram, paroxetine, sertraline, and their metabolites by gas chromatography mass spectrometry. Journal of Chromatographic Science 36: 365-371.

33. Hans JL, Werner W, Günter F (2002) Improved sample preparation for the quantitative analysis of paroxetine in human plasma by stable isotope dilution negative ion chemical ionisation gas chromatography mass spectrometry. Journal of Chromatography B 753: 353-357.

34. Chien L, Emily SG, Sidney HK, Alan N, Ronald TC, et al. (2000) Determination of paroxetine levels in human plasma using gas chromatography with electron capture detection. Journal of Chromatography 2: 275-279.

35. Labat L, Deveaux M, Dalle P, Dubost JP (2002) Separation of new antidepressants and their metabolites by micellar electrokinetic capillary chromatography. Journal of Chromatography 1: 17-23.

36. Walsh M, Belal F, El-Enany N, Elmans H (2011) Spectrofluorimetric determination of paroxetine HCl in pharmaceuticals via derivatization with 4-chloro-7-nitrobenzo-2-oxa-1,3-diazole (NBD-Cl). J Fluoresc 21: 105-112.

37. Pollack MH, Simon NM, Worthington JJ, Doyle AL, Peters P, et al. (2003) Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol 17: 276-282.

38. Geetharam Y, Praveen S (2014) Development and validation of a stability-indicating HPLC method for the simultaneous determination of paroxetine hydrochloride and clonazepam in pharmaceutical dosage forms. International J Pharm 438: 448-457.

39. http://www.medguideindia.com

40. ICH Harmonized Tripartite Guideline (1996) Validation of Analytical Procedure. Text and Methodology, Q2 (R1) Current Step 4 Version, Parent Guidelines on Methodology.

41. Miller JC (2005) Statistics and Chemometrics for Analytical Chemistry. In: Harlow. 5th edn. Pearson Education Limited.

42. British Pharmacopoeia (2010) 1: 548.

43. British Pharmacopoeia (2010) 2: 1618-1619.